Insulin receptor
Assets acting on this target.
- Class
- Insulin
- Notes
- mechanism wave 2026-08-24 (DeepSeek draft; registry text of NCT05441631 names the target); source: https://clinicaltrials.gov/study/NCT05441631
By indication
Related mechanisms
Insulin receptor drugs compared
9 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| insulin aspartNovoLog | Novo Nordisk | peptide | Approved | Approved in Type 1 Diabetes; Approved in Type 2 Diabetes |
| Insulin aspart (Fiasp)Fiasp | Novo Nordisk | peptide | Approved | Approved in Type 1 Diabetes; Approved in Type 2 Diabetes |
| insulin glulisineApidra | Sanofi | peptide | Approved | Approved in Type 1 Diabetes; Approved in Type 2 Diabetes |
| Insulin LisproHumalog | Eli Lilly | peptide | Approved | Approved in Type 1 Diabetes; Approved in Type 2 Diabetes |
| Insulin lispro (Lyumjev)Lyumjev | Eli Lilly | peptide | Approved | Approved in Type 1 Diabetes; Approved in Type 2 Diabetes |
| insulin NPHHumulin N | Eli Lilly | peptide | Approved | Approved in Type 1 Diabetes; Approved in Type 2 Diabetes |
| SAR341402 | Sanofi | peptide | Approved | Approved in Type 2 Diabetes |
| THDB0206 | Adocia, Tonghua Dongbao Pharmaceutical | peptide | Phase 3 | Phase 3 in Type 2 Diabetes |
| Insulin aspart (AT278) | Arecor Limited | peptide | Phase 1 | Phase 1 in Type 2 Diabetes |